Notice: The ASA website will be unavailable beginning Thursday, May 17 from 4 p.m. until noon (CDT) on May 18 due to system maintenance.

>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS

October 13 - 17 2012, 12:00 AM - 12:00 AM

ANESTHESIOLOGY 2012

>

FDA MEDWATCH ALERTS

RSS

May 16, 2012

Hydromorphone Hydrochloride Recall

Summary:

Hydromorphone Hydrochloride Recall

April 18, 2012

Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume

Summary:

Customer report of two Carpujects syringes containing more than the 1 mL labeled fill volume. Opioid pain medications such as morphine have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), and low blood pressure.

March 05, 2012

Cardiac Science Powerheart, CardioVive, CardioLife; GE Responder and Responder Pro; and Nihon-Kohden Automated External Defibrillators (AEDs): Class I Recall - Defective Component

Summary: FDA notified healthcare professionals and medical care organizations of the Class 1 recall of the listed AEDs which contain a component that may fail unexpectedly due to a defect. If the component were to fail during a rescue attempt, the AED may not deliver defibrillation therapy, causing serious adverse health consequences, including death. The unit’s self test may not detect the failure or impending failure of the component.

>

ASA FEATURED PRODUCT

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-12CE

... Read more »

Single Copies, Member Price: $300

ASA Urges CMS to Include Pain Care in Essential Health Benefits Package

Friday, February 03, 2012

In a recent comment letter, the Pain Care Coalition, which includes the American Society of Anesthesiologists, American Academy of Pain Medicine, American Headache Society, and American Pain Society, urged CMS to include the assessment, diagnosis, treatment and management of a patient’s acute or chronic pain in the essential health benefits (EHB) package under the Patient Protection and Affordable Care Act (PPACA). 

PPACA directs the Secretary of Health and Human Services to define EHB, and in December 2011, CMS released the Essential Health Benefits Bulletin (Bulletin) which details the agency’s intended regulatory approach.  According to the Bulletin, CMS intends to propose that each state pick a benchmark plan among those plans currently offered in the state, and the benefits and services included in the benchmark plan would be the EHB package.  EHB must include coverage of ten mandated benefit categories identified in PPACA (ambulatory patient services, emergency services, hospitalization, maternity and newborn care, mental health and substance use disorder services, prescription drugs, rehabilitative and habilitative services and devices, laboratory services, preventive and wellness screenings and chronic disease management, and pediatric services).  The benchmark plan will serve as a reference plan, and health insurance issuers in the states must offer benefits “substantially equal” to the benefit package offered by the benchmark plan.  Beginning in 2014, non-grandfathered plans in the individual and small group markets both inside and outside of the Exchanges must cover EHB. 

In the comment letter, the Pain Care Coalition explains that pain care fits poorly in CMS’s strictly categorical approach to benefit design.   While pain care may be viewed as falling within one or more of PPACA’s ten mandated coverage categories, CMS’s intended approach does not reflect that pain care is often complex and crosses multiple care settings.  For that reason, the Pain Care Coalition urged CMS to “adopt a minimum standard for health insurance coverage that speaks to comprehensive pain care across other benefit categories.”  In short, “one element of an EHB package should be the adequate assessment, diagnosis, treatment and management of a patient’s acute or chronic pain.”

The Pain Care Coalition’s comment letter on the EHB package is available here, and the Bulletin is available here

Click here for additional information on ASA’s advocacy activities related to pain medicine.     

« Back to Washington Alerts